Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species / Nithya Srinivas, Elias P. Rosen, William M. Gilliland Jr, Martina Kovarova, Leila Remling-Mulder, Gabriela De La Cruz, Nicole White, Lourdes Adamson, Amanda P. Schauer, Craig Sykes, Paul Luciw, J. Victor Garcia, Ramesh Akkina, Angela D. M. Kashuba
Abstract 1. Antiretroviral concentrations in cerebrospinal fluid (CSF) are used as surrogate for brain tissue, although sparse data support this. We quantified antiretrovirals in brain tissue across preclinical models, compared them to CSF, and calculated 90% inhibitory quotients (IQ 90 ) for nonhuman primate (NHP) brain tissue. Spatial distribution of efavirenz was performed by mass-spectrometry imaging (MSI). 2. HIV or RT-SHIV-infected and uninfected animals from two humanized mouse models (hemopoietic-stem cell/RAG2-, n = 36; bone marrow-liver-thymus/BLT, n =13) and an NHP model (rhesus macaque, n =18) were dosed with six antiretrovirals. Brain tissue, CSF (NHPs), and plasma were collected at necropsy. Drug concentrations were measured by LC-MS/MS. Rapid equilibrium dialysis determined protein binding in NHP brain. 3. Brain tissue penetration of most antiretrovirals were >10-fold lower ( p 13-fold lower ( p 1 in all animals and 2-fold greater white versus gray matter concentration. 4. Brain tissue penetration varied across animal models for all antiretrovirals except raltegravir, and extrapolating brain tissue concentrations between models should be avoided. With the exception of efavirenz, CSF is not a surrogate for brain tissue concentrations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Xenobiotica - 49(2019), 10, Seite 1192-1201 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Srinivas, Nithya [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Antiretrovirals |
|---|
| Umfang: |
1 Online-Ressource (10 p) |
|---|
| doi: |
10.1080/00498254.2018.1539278 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011209585 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011209585 | ||
| 003 | DE-627 | ||
| 005 | 20230720210318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/00498254.2018.1539278 |2 doi | |
| 035 | |a (DE-627)KFL011209585 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/00498254.2018.1539278 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Srinivas, Nithya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species |c Nithya Srinivas, Elias P. Rosen, William M. Gilliland Jr, Martina Kovarova, Leila Remling-Mulder, Gabriela De La Cruz, Nicole White, Lourdes Adamson, Amanda P. Schauer, Craig Sykes, Paul Luciw, J. Victor Garcia, Ramesh Akkina, Angela D. M. Kashuba |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (10 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract 1. Antiretroviral concentrations in cerebrospinal fluid (CSF) are used as surrogate for brain tissue, although sparse data support this. We quantified antiretrovirals in brain tissue across preclinical models, compared them to CSF, and calculated 90% inhibitory quotients (IQ 90 ) for nonhuman primate (NHP) brain tissue. Spatial distribution of efavirenz was performed by mass-spectrometry imaging (MSI). 2. HIV or RT-SHIV-infected and uninfected animals from two humanized mouse models (hemopoietic-stem cell/RAG2-, n = 36; bone marrow-liver-thymus/BLT, n =13) and an NHP model (rhesus macaque, n =18) were dosed with six antiretrovirals. Brain tissue, CSF (NHPs), and plasma were collected at necropsy. Drug concentrations were measured by LC-MS/MS. Rapid equilibrium dialysis determined protein binding in NHP brain. 3. Brain tissue penetration of most antiretrovirals were >10-fold lower ( p 13-fold lower ( p 1 in all animals and 2-fold greater white versus gray matter concentration. 4. Brain tissue penetration varied across animal models for all antiretrovirals except raltegravir, and extrapolating brain tissue concentrations between models should be avoided. With the exception of efavirenz, CSF is not a surrogate for brain tissue concentrations | ||
| 653 | |a Antiretrovirals | ||
| 653 | |a brain tissue | ||
| 653 | |a cerebrospinal fluid | ||
| 653 | |a efavirenz | ||
| 653 | |a HIV | ||
| 653 | |a mass-spectrometry imaging | ||
| 653 | |a protein binding | ||
| 700 | 1 | |a Rosen, Elias P. |e verfasserin |4 aut | |
| 700 | 1 | |a Gilliland Jr, William M. |e verfasserin |4 aut | |
| 700 | 1 | |a Kovarova, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Remling-Mulder, Leila |e verfasserin |4 aut | |
| 700 | 1 | |a De La Cruz, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a White, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Adamson, Lourdes |e verfasserin |4 aut | |
| 700 | 1 | |a Schauer, Amanda P. |e verfasserin |4 aut | |
| 700 | 1 | |a Sykes, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Luciw, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, J. Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Akkina, Ramesh |e verfasserin |4 aut | |
| 700 | 1 | |a Kashuba, Angela D. M. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Xenobiotica |d Abingdon : Taylor & Francis Group, 1971 |g 49(2019), 10, Seite 1192-1201 |h Online-Ressource |w (DE-627)KFL000005959 |w (DE-600)1485113-1 |w (DE-576)079719163 |x 1366-5928 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2019 |g number:10 |g pages:1192-1201 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/00498254.2018.1539278 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2019 |e 10 |h 1192-1201 | ||